No combination chemotherapy has been shown yet to be more effective in metastatic breast cancer (MBC) patients who did not either respond to taxanes and anthracyclines or recurred thereafter. We aimed to report in short term the effect and toxicity results of capecitabine and oral cyclophosphamide combination in MBC patients with anthracyclin and taxane resistance. Between January and September 2007, totally 11 patients were enrolled. All of them had received anthracyclines and taxanes previously either in metastatic or adjuvant setting. They were given capecitabine (1000 mg/m 2 bid) and oral cychlophosphamide (30 mg/m 2 tid) on days 1 to 14 every 3 weeks.
INTRODUCTION
Metastatic breast cancer (MBC) is an incurable disease. Palliation of symptoms, maintenance of quality of life and tolerability of treatment are particularly important for patients. The most commonly used chemotherapeutic regimens in the treatment of MBC include anthracyclines and taxanes, either in sequence or in combination. 1 An increasing number of patients receive an anthracycline-taxane combination as adjuvant therapy, requiring the development of new combinations for the treatment of metastatic disease. No monotherapy or combination chemotherapy has been shown yet to be more effective in metastatic breast cancer patients who did not either respond to taxanes and anthracyclines or recurred thereafter.
Both cyclophosphamide and capecitabine have some efficacy in breast cancer. Cyclophosphamide is typically used as a component of combination regimens, such as CAF (cyclophosphamide, adriamycin, 5-fluorouracil) or TAC (docetaxel, adriamycin, cyclophosphamide). The oral fluoropyrimidine capecitabine, generates 5-fluorouracil preferentially at the tumor site through exploitation of the significantly higher concentration of thymidine phosphorylase in tumor versus normal tissue. 2 Capecitabine monotherapy has demonstrated consistently high activity and excellent tolerability in anthracycline-and/or taxane-pretreated MBC. 3, 4 The high single-agent activity and good tolerability of capecitabine makes it an attractive combination partner.
Several surveys have shown that most patients prefer oral treatment instead of intravenous therapy. [5] [6] [7] Nevertheless, a minority of patients prefer intravenous therapy because they believe that oral therapy is less effective than intravenous treatment. [7] [8] [9] We aimed to report the efficacy and toxicity of capecitabine and oral cyclophosphamide combination in anthracyclin and taxane resistant MBC patients.
PATIENTS AND METHODS
Between January and September 2007, totally 11 histologically confirmed MBC patients were enrolled into the study. All of them had received anthracyclines and taxanes previously either in metastatic or adjuvant setting. They received capecitabine (1000 mg/m 2 bid) and oral cychlophosphamide (30 mg/m 2 tid) on days 1 to 14 every 3 weeks. The chemotherapy continued until progression or intolerance. Depending on the RECIST criteria 10 , response to treatment was evaluated with imaging studies every three cycles. Duration of response was calculated by counting the months elapsed from the established response to progression or to analysis time. Toxicity was graded according to the NCI Common Terminology Criteria for Adverse Events version 3.0.
RESULTS
Patient's and tumor characteristics were summarized in Table 1 . The median age was 48 years (range, 33-60). All patients had a good performance status (ECOG PS 0-2). All of them had received anthracyclines and taxanes previously either in metastatic or adjuvant setting. Seven patients had received trastuzumab previously, either as monotherapy or as part of combination chemotherapy. The median number of previous chemotherapy lines given was 3 (range: 2-7). The major metastatic sites were lung, bone and liver in order.
Median follow-up was 5 months (range: 2-11). The patients received a median of 8 cycles chemotherapy (range: 2-15). All of 11 patients were evaluated for response: 4 (36.4%) patients achieved a partial response and none had complete response ( Table 2 ). All patients with partial response had received capecitabine monotherapy previously. Median duration of response was 5 (range: 3-8) months. Two (18.1%) patients died related to the disease progression.
Toxicity evaluations are summarized in Table 3 . One (9.1%) patient had grade 3 hand-foot syndrome. No grade 4-5 toxicity observed. 
DISCUSSION
There is no evidence that any specific chemotherapy combination is superior to any other in metastatic breast cancer patients who did not either respond to taxanes and anthracyclines or recurred thereafter. New treatment strategies are increasingly needed for patients failing these therapies or who are at risk of cumulative toxicities. There is no study in the literature investigating the efficacy of the capecitabine and cyclophosphamide combination after taxanes and antracyclines in MBC patients. Capecitabine has been demonstrated to be effective in this setting with an overall response rate of 9-28%, and overal survival between 9.4 and 15.2 months in several phase II-III trials, either as monotherapy or combination chemotherapy.
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In a phase I study investigating the feasibility of the combination of capecitabine (1000-1331 mg/m 2 on days 1 to 28 every 4 weeks) and oral cyclophosphamide (50-125 mg/m 2 on days 1-to 14, every 4 weeks), this combination was found to be feasible and tolerable. 15 Shinji et al reported the combination of capecitabine 829 mg/m 2 bid and oral cyclophosphamide 33 mg/m 2 bid on days 1 to 14 every 3 weeks to be an active and tolerable regimen. 16 In that study, 16 patients received this combination in the first line, and the overall response rate was 40%. However in our study overall response rate was 36.4% and this rate was achieved in patients with previous taxan or antracycline exposure (the median number of previous chemotherapy lines was 3). All of our patients with cerbB2 positive tumors had received trastuzumab. Interestingly patients who progressed on previous capecitabine monotherapy or recurred thereafter responded to the capecitabine and cyclophosphamide combination, cyclophosphamide might have broken the capecitabine resistance. We didnot give the median progression free and median overall survival due to short follow-up. However, the median duration of response was 5 months.
This combination had a very low toxicity profile. No grade 4 to 5 toxicity was observed. Only one grade 3 non-hematological toxicity (hand-foot syndrome) was diagnosed. Toxicity profile in our study is similar to the studies mentioned above. 15, 16 In conclusion, capecitabine and oral cyclophosphamide combination is a promising and well tolerated regimen in patients who previously had received taxanes and anthracyclines and in patients with cerbB2 positive tumors who received trastuzumab previously. Patients who were unresponsive to previous capecitabine or who recurred thereafter may respond to capecitabine and oral cyclophosphamide combination.
